News
FDA Approves Rasburicase as Initial Therapy for Adults at Risk for Tumor Lysis Syndrome
FDA Approves Rasburicase as Initial Therapy for Adults at Risk for Tumor Lysis Syndrome
E Okin Powers
20090920
2009 Oct 20
OncologySTAT Editorial Team
FDA Approves Rasburicase as Initial Therapy for Adults at Risk for Tumor Lysis Syndrome
OncologySTAT Editorial Team. 2009 Oct 20, E Okin Powers
On October 16, the US Food and Drug Administration gave its stamp of approval for a new indication for rasburicase. The recombinant uricolytic agent can now be used in the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to cause elevations of plasma uric acid and lead to the development of the tumor lysis syndrome (TLS). Tumor lysis syndrome is a potentially life-threatening...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
